Table I:
Clinical characteristics of the study population.
| ID | Age (years) | Gender | Ethnicity | CD4+ (cells/uL) | CD4+ (%) | CD8+ (cells/uL) | CD8+ (%) | CD4:CD8 ratio | Nadir CD4+ (cells/uL) | ART regimen | Peak Viral Load (copies/mL) | Duration Viral Load <50 (years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRA001 | 64 | Male | Caucasian | 403 | 24 | 1061 | 63 | 0.380 | 10 | ATV, TDF/FTC | 148,430 | 14.1 |
| PRA002 | 48 | Male | Caucasian | 1460 | 47 | 793 | 26 | 1.841 | 698 | ABC/3TC, EFV | N/A | N/A |
| PRA003 | 49 | Male | Caucasian | 833 | 31 | 767 | 29 | 1.086 | 218 | TDF/FTC, DRV, RTV | 78,300 | 11.5 |
| PRA004 | 55 | Male | Caucasian | 1036 | 40 | 1069 | 42 | 0.969 | 266 | TAF/FTC, DTG | 100,000 | 11.1 |
| PRA005 | 49 | Male | Caucasian | 388 | 28 | 717 | 51 | 0.541 | 168 | TAF/FTC, MVC | 147,000 | 12.0 |
| PRA006 | 48 | Male | Caucasian | 864 | 38 | 864 | 39 | 1.000 | 538 | EVG/TAF/FTC/COBI | 118,800 | 6.1 |
| PRA007 | 47 | Male | Caucasian | 705 | 32 | 1034 | 47 | 0.682 | 122 | DRV/COBI, TAF/FTC | 548,000 | 6.5 |
| PRA008 | 38 | Male | Other (PNG) | 281 | 25 | 328 | 30 | 0.857 | 168 | EVG/TAF/FTC/COBI | 63,300 | 8.7 |
| PRA009 | 49 | Male | Caucasian | 474 | 25 | 1085 | 56 | 0.437 | 42 | EVG/TAF/FTC/COBI | 211,930 | 7.0 |
| PRA010 | 48 | Male | Caucasian | 484 | 28 | 895 | 52 | 0.541 | 411 | TAF, FTC, RPV | N/A | N/A |
| PRA011 | 53 | Male | Caucasian | 735 | 37 | 810 | 41 | 0.907 | 300 | ABC/3TC, EFV | 365,000 | 11.2 |
| Median (IQR) | 49 (48 – 51) | N/A | N/A | 705 (439 – 849) | 31 (27 – 38) | 864 (780 – 1048) | 42 (35 – 52) | 0.857 (0.541– 0.985) | 218 (145 – 356) | N/A | 147,000 (100,000 – 211,930) | 11.1 (7 – 11.5)1 |
1
3TC, Lamivudine; ABC, Abacavir; ATV, Atazanavir; COBI, Cobicistat; DRV, Darunavir; DTG, Dolutegravir; EFV, Efavirenz; EVG, Elvitegravir; FTC, Emtricitabine; MVC, Maraviroc; RPV, Rilpivirine; RTV, Ritonavir; TAF, Tenofovir Alafenamide; TDF, Tenofovir Disoproxil Fumarate.